The review found no eligible studies for this question.
It is very uncertain whether calcineurin inhibitor regimen changes complete remission compared with no calcineurin inhibitor regimen (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether calcineurin inhibitor regimen changes infection compared with no calcineurin inhibitor regimen (very low certainty).
It is very uncertain whether calcineurin inhibitor regimen changes malignancy compared with no calcineurin inhibitor regimen (very low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in graft loss compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: CMV infection compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: malignancy compared with to standard dose CNI (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in death compared with to standard dose CNI (moderate certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in acute rejection compared with to standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal showed no clear difference in death compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal probably leads to higher acute rejection compared with standard dose CNI (moderate certainty).
Calcineurin inhibitor (CNI) withdrawal may leads to lower graft loss compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal showed no clear difference in adverse events: CMV infection compared with standard dose CNI (low certainty).